Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer
1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study ...
1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study ...
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) ...
Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective ...
Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation System There are ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.